IMMUNOPRECISE ANTIBODIES LTD.

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

Retrieved on: 
Mardi, mars 29, 2022
Infectious Diseases, Biotechnology, Health, TSX Venture Exchange, Company, SPA, Therapy, Drug development, Epitope, Multiomics, NASDAQ, DNA, Transaction, Forward-looking statement, Multimedia, Non-competitive inhibition, Board, Biotechnology, Research, Genomics, Precision medicine, RNA, Data analysis, Language, Employment, TSX, Metabolomics, Software, NLP, Biology, Technology, Database, Acquisition, Time, Mass spectrometry, Algorithm, Phrase, News, Food and Drug Administration Amendments Act of 2007, Proteomics, VWAP, AI, Protein, Policy, Antibody, Fine chemical, Medical imaging, Risk management, Life insurance, Online gambling, Security (finance), Property management, Audit, Real estate, IPA, IMMUNOPRECISE ANTIBODIES LTD., BIOSTRAND BV, BIOKEY BV, BIOCLUE BV

BioStrand offers a revolutionary, cloud-based solution to perform multi-omics research faster and more accurately, with more effective data analysis.

Key Points: 
  • BioStrand offers a revolutionary, cloud-based solution to perform multi-omics research faster and more accurately, with more effective data analysis.
  • The acquisition enhances IPAs position as a leader in the field of biotherapeutics - BioStrands software and AI capabilities complement every sector of IPAs business.
  • BioStrands semantically driven natural language process (NLP) approach makes omics data research truly effective and differentiates IPAs offerings to provide a powerful and unique opportunity for IPAs clients.
  • Total consideration of 20 million, of which 2 million will be paid in cash, subject to adjustments, and 18 million will be paid in equity.

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing

Retrieved on: 
Jeudi, mai 20, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious diseases, Clinical trials, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, IPA’s PolyTope Platform, ImmunoPrecise Antibodies Ltd., IPA’S POLYTOPE PLATFORM, IMMUNOPRECISE ANTIBODIES LTD.

To our knowledge, this is the first publicly reported study demonstrating in vivo synergistic effects in SARS-CoV-2 infected animals using a dose-escalation study.

Key Points: 
  • To our knowledge, this is the first publicly reported study demonstrating in vivo synergistic effects in SARS-CoV-2 infected animals using a dose-escalation study.
  • In IPA\xe2\x80\x99s preclinical study:\nIPA\xe2\x80\x99s TATX-03b PolyTope antibody cocktail was administered as a single dose to hamsters that had been infected with SARS-CoV-2 mutant D614G.
  • TATX-03b is highly efficacious, clearing replication-competent viral titer to undetectable levels in the lung in 100% (five out of five) animals.
  • \xe2\x80\x9cThese variants will continue to create a moving target for vaccines and therapeutics that were not rationally designed to withstand the emergence of novel variants and strains.